PCM
RCKT icon

Pentwater Capital Management’s Rocket Pharmaceuticals RCKT Stock Holding History

Pentwater Capital Management’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-196,800
Closed -$3.86M – 155
2015
Q2 		$3.86M Buy
196,800
+21,800
+12% +$483K 0.02% 128
2015
Q1 		$3.79M Buy
+175,000
New +$4.11M 0.03% 118

Other funds holding RCKT

DPA
Devon Park Associates $30.8M AUM 0.85% 1-Year Est. Return
RCP
Rho Capital Partners New York $20.4M AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
RIM
RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
EAM
EverPoint Asset Management Stamford, Connecticut $5.38B AUM 21.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Pentwater Capital Management's RCKT Position: Q3 2015 in Review

Pentwater Capital Management sold out of Rocket Pharmaceuticals (RCKT) in Q3 2015, closing a stake of 196,800 shares — an estimated $3.86M sold.

Pentwater Capital Management first reported a position in RCKT in Q1 2015 and held it in 2 quarters. The position peaked at $3.86M in Q2 2015. 53 funds tracked by Wall St. Rank hold RCKT as of Q3 2015.

  • Pentwater Capital Management reported no remaining Rocket Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
  • Pentwater Capital Management sold 196,800 Rocket Pharmaceuticals shares in Q3 2015, an estimated $3.86M.
  • Pentwater Capital Management first reported a position in Rocket Pharmaceuticals in Q1 2015 and held it in 2 quarters.
  • Pentwater Capital Management's Rocket Pharmaceuticals position peaked at $3.86M in Q2 2015.
  • 53 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q3 2015.

Based on Pentwater Capital Management's 13F filing for Q3 2015, filed 16 Nov 2015.